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Introduction: The crucial role of innate immunity in the pathogenesis of systemic sclerosis (SSc) is well established,
and in the past few years the hypothesis that Toll-like receptor 4 (TLR4) activation induced by endogenous ligands
is involved in fibrogenesis has been supported by several studies on skin, liver, and kidney fibrosis. These findings
suggest that TLR4 activation can enhance transforming growth factor beta (TGF-β) signaling, providing a potential
mechanism for TLR4/Myeloid differentiation factor 88 (MyD88)-dependent fibrosis.
Methods: The expression of TLR4, CD14 and MD2 genes was analyzed by real-time polymerase chain reaction from skin
biopsies of 24 patients with diffuse cutaneous SSc. In order to investigate the effects of the chronic skin exposure to
endotoxin (Lipopolysaccharide (LPS)) in vivo we examined the expression of inflammation, TGF-β signaling and cellular
markers genes by nanostring. We also identified cellular subsets by immunohistochemistry and flow cytometry.
Results: We found that TLR4 and its co-receptors, MD2 and CD14, are over-expressed in lesional skin from patients with
diffuse cutaneous SSc, and correlate significantly with progressive or regressive skin disease as assessed by the Delta
Modified Rodnan Skin Score. In vivo, a model of chronic dermal LPS exposure showed overexpression of proinflammatory
chemokines, recruitment and activation of macrophages, and upregulation of TGF-β signature genes.
Conclusions: We delineated the role of MyD88 as necessary for the induction not only for the early phase of
inflammation, but also for pro-fibrotic gene expression via activation of macrophages. Chronic LPS exposure might be
a model of early stage of SSc when inflammation and macrophage activation are important pathological features of
the disease, supporting a role for innate immune activation in SSc skin fibrosis.Introduction
Systemic sclerosis (SSc) is a chronic connective tissue dis-
ease of unknown etiology, characterized by heterogeneous
clinical manifestations and an unpredictable course. Hall-
marks of this disease are inflammation, autoimmunity,
vascular damage, and fibrosis [1]. Fibrosis appears most
likely induced by inappropriate production of transfor-
ming growth factor-β (TGF-β), or other pro-fibrotic cyto-
kines, such as connective tissue growth factor (CTGF),* Correspondence: stifanog@bu.edu
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stated.IL-13 and thymic stromal lymphopoietin (TSLP), inducing
excessive accumulation of extracellular matrix (ECM)
components by activated fibroblasts [2-4]. Although the
stimulus for production of pro-fibrotic cytokines in SSc
remains uncertain, these cytokines might be released or
activated by infiltrating immune cells that are most
prominent during the inflammatory stage of SSc [2,3,5,6].
The importance of immune-mediated pathogenesis of SSc
is supported by several observations, including the close
relationship in clinical features and genetic associations
with systemic lupus erythematosus (SLE), where inflam-
mation appears to be induced or amplified by activation of
Toll-like receptors (TLRs) [7].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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plasmic domains (ectodomains) responsible for ligand
binding, and intracellular Toll-interleukin 1 (IL-1) receptor
(TIR) domains necessary for downstream signal transduc-
tion. Each TLR can recognize specific microbial compo-
nents, known as pathogen associated molecular patterns
(PAMPs). Some TLRs (TLR2, TLR4, TLR5, and TLR6) are
expressed on the cellular surface, and others (TLR3, TLR7,
TLR8, and TLR9) are normally located in intracellular
compartments [8,9].
TLR4, one of the first TLRs identified, was recognized
as the receptor able to respond to bacterial lipopolysac-
charide (LPS), a component of the outer membrane of
gram-negative bacteria, causing septic shock [10]. On the
cell surface TLR4 forms a complex with myeloid differen-
tiation factor-2 (MD2) acting as the main LPS-binding
component [11]. Additional proteins, such as LPS-binding
protein (LBP), a soluble plasma protein, and CD14 are
also involved in LPS binding [12]. CD14, a glycosyl-phos-
phatidylinositol (GPI)-anchored protein without trans-
membrane and intracellular domains, is expressed on the
cellular surface (mCD14) or produced in a soluble form
(sCD14). CD14 enhances LPS responsiveness by binding
LPS and facilitating LPS transfer to TLR4/MD-2 [13]. It is
primarily expressed on cells of the monocyte/macrophage
lineage, but is also expressed at low levels on neutrophils,
non-myeloid cells, B-lymphocytes, endothelial cells and
mammary epithelial cells. Cells that do not express
mCD14 can use sCD14 to recognize LPS [14,15]. After
the binding of LPS to TLR4, signaling transduction follows
two different pathways: a Myeloid differentiation factor 88
(MyD88)-dependent pathway activated by all TLRs except
TLR3, and a MyD88-independent pathway requiring the
TIR-containing adaptor molecule (TICAM), also used by
TLR3. Both pathways trigger downstream signaling cas-
cades inducing the production of proinflammatory cyto-
kines, chemokines, and type I interferon [8].
Interest in TLR4 as a pro-fibrotic mediator has been
stimulated by the observation that endogenous molecules
can interact directly or indirectly with TLR4, such as
connective tissue molecules (hyluronan, fibrinogen, al-
ternatively spliced fibronectin extradomain A (Fn-EDA),
tenascin C, and biglycan), heat-shock proteins (Hsp60,
Hsp70, Gp69), cellular stress protein (high mobility group
box 1 protein (HMGB1), beta-defensin 2, heparan sulfate,
and surfactant protein-A [16]. In the past few years, the
hypothesis that TLR4 activation induced by endogenous
ligands is involved in fibrogenesis has been supported by
several studies on skin, liver, and kidney fibrosis [17-19].
These studies have led to the notion that damage asso-
ciated molecular patterns (DAMPs) from these or other
proteins may become exposed during inflammation, cau-
sing or perpetuating inflammation and fibrosis. Other
studies have suggested that TLR4 can directly enhanceTGF-β signaling [17,20], providing a potential mechanism
for TLR4-mediated fibrosis.
In the present study, we sought to better understand
the role of TLR4 activation in SSc, by investigating the
clinical correlations between the expression of TLR4 and
its co-receptors, MD2 and CD14, in the skin of SSc pa-




The Boston University Medical Center Institutional Review
Board (Boston, MA, USA) reviewed and approved the con-
duct of this study. Informed consent was obtained from all
patients and healthy subjects (diffuse cutaneous SSc
(dcSSc) (n = 24) according to diagnostic [21] and subtype
criteria [22] and healthy subjects (n = 11)). Skin biopsies
were obtained from over the dorsal mid forearm and im-
mediately stored in RNAlater (Qiagen) at −80°C until RNA
isolation. The modified Rodnan skin score (MRSS) was de-
termined for each patient on the day of the biopsy [23].
RNA isolation and quantitative real-time PCR
Human skin biopsies were placed in RLT lysis buffer
(Qiagen), minced and disrupted using a Polytron ho-
mogenizer (Capitol Scientific, Austin, TX, USA). RNAs
were isolated in accordance with the RNeasy Mini Kit
protocol (Qiagen). The concentration of total RNA iso-
lated was measured (Nanodrop 1000; Thermo Scientific)
and 200 ng of RNA was used to synthesize complemen-
tary DNAs (cDNAs) according to the protocol for Super-
Script II reverse transcriptase (Invitrogen) using random
primers. cDNAs were used as templates for quantitative
real-time PCR analysis with gene expression assays (Taq-
Man; Applied Biosystems), using the following primer
pairs: 18S (4319413E); CD14 (Hs02621496_s1); MD2
(Hs01026734_m1); TLR4 (Hs00152939_m1).
In vivo administration of LPS
Mice wild-type (WT) (C57BI/6 WT), TLR4−/− (B10ScN-
Tlr4lps-del/JthJ), and TLR2−/− (B6.129-Tlr2tm1Kir/J)
were obtained from Jackson Laboratories; C57BI/6/
MyD88−/−mice were obtained from Dr Shizuo Akira [24].
Briefly, mice were anesthetized by intraperitoneal (i.p.)
injection of ketamine (100 mg/kg) and xylazine (5 mg/kg).
Osmotic pumps (Alzet) designed to deliver lipopolysac-
charide (LPS-EB ultrapure Invivogen: Ultra pure lipopoly-
saccharide from Escherichia coli 0111:B4 strain- TLR4
ligand) at 0.5 mg/ml and 0.1 mg for a total dose of 200 μl
released over 7 or 28 days, or sterile PBS (Gibco) were
sterilely implanted subcutaneously in 6- to 8-week-old
mice. The concentration of LPS used in 1-week pumps
was 200 μg/ml and in 4-week pumps it was 800 μg/ml.
Thus, the rate of release of LPS per hour was the same in
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1 week or 4 weeks, mice were sacrificed and skin (approxi-
mately 1 cm2) surrounding the pump outlet was homoge-
nized in Trizol (Invitrogen) for preparation of RNA and in
some experiments fixed in formalin for histology and im-
munohistochemistry. All the procedures were approved
by the institutional animal care and used committee at
Boston University Medical Campus.
Anti TGF-β antibody treatment
To block TGF-β gene expression, WT mice were treated
with i.p. injections of anti TGF-β antibodies (α-TGF-
β1,2,3, 125 μg/per mouse, R&D Systems,) on the same
day of LPS pump insertion, and on days 2 and 5 after
pump insertion. Control mice were treated with Isotype
IgG1 i.p. injection (125 μg/per mouse, R&D Systems).
Mice were sacrificed and skin (approximately 1 cm2)
surrounding the pump outlet was homogenized in Trizol
(Invitrogen) for preparation of RNA or fixed in formalin
for immunohistochemistry.
Monocyte-macrophage depletion
To explore the importance of monocytes/macrophages,
we used a macrophage-deficient model achieved by diph-
theria toxin (DT) treatment of mice selectively expressing
the diphtheria toxin receptor in CD11b + cells. Itgam
(CD11b)-DTR (B6.FVB-Tg(ITGAM-DTR/EGFP)34Lan/J)
mice were obtained from Jackson Laboratories. These
transgenic mice have a CD11b promoter that drives the
expression of the human DT receptor leading to the
depletion of monocytes after receptor ligation. To induce
monocyte/macrophage depletion, 25 ng of DT per gram
of body weight was given by i.p. injection on the same day
of LPS or PBS pump insertion, and a second time at
48 hours. Mice were sacrificed at day 5. ITGAM-DTR
control mice received PBS i.p. injections (CD11b-DTr
LPS/PBS). Skin (approximately 1 cm2) surrounding the
pump outlet was homogenized in Trizol (Invitrogen) for
preparation of RNA or fixed in formalin or optimal
cutting temperature compound (OCT) for immuno-
histochemistry or immunofluorescence, respectively. Im-
munofluorescent staining with CD11b and F4/80 (BD
Biosciences) of distal skin was used to document mono-
cyte/macrophage depletion (data not shown).
Immunohistochemistry
Immunohistochemistry was performed using the Vectastain
ABC kit (Vector Laboratories) according to the manufac-
turer’s instructions on formalin-fixed, paraffin-embedded
skin tissue sections. Briefly, sections were deparaffinized,
rehydrated in acidic antigen-retrieval solution (pH = 6),
and blocked with FC Blocker and Background blocker
(Innovex) and normal blocking serum for 30 minutes.
Sections were stained with hematoxylin and eosin. Thesections were then incubated overnight at 4°C with anti-
bodies against CD163, Arginase-1 (ARG-1) and MAC-3
(CD163: Epitomics, Burlingame, CA, USA, dilution 1:200
in blocking buffer; ARG-1: LifeSpan Biosciences, Inc.
dilution 1:250; MAC-3: BD Pharmingen™, dilution 1:100)
followed by incubation for 30 minutes with a biotinylated
secondary antibody solution. The sections were developed
by Dako Chromogen System and counterstained with
hematoxylin. Isotype control staining was performed for
each antibodies used (data not shown).
Flow cytometry
For analysis of cellular infiltrate, mouse skin was minced
and followed by enzymatic digestion with 0.28 U/ml
Liberase 3 (Roche) for 20 minutes at 37°C, passed through
a 70-μm filter washed in Roswell Park Memorial Institute
medium (RPMI) without serum, and counted. Flow cy-
tometry was performed using fluorochrome conjugated
monoclonal antibodies to mouse CD11b (BD Biosciences).
Macrophages were identified as CD11b+SSClo, and granu-
locytes as CD11b+SSChi. Cells were acquired with the
LSRII Flow Cytometer (BD Biosciences) and the data were
analyzed with FlowJo software (Tree Star).
Nanostring analysis
Skin from mice treated with PBS and LPS was analyzed
using nanostring technology [25]. A set of 50 genes,
including inflammatory genes, macrophages markers,
TGF-β-regulated genes, and others, were analyzed: 100 ng
of RNA per sample was used and gene expression was
normalized to the expression of eight housekeeping genes.
The analysis was performed using GraphPad Software,
Inc, and clustered by Cluster 3.0 software.
Statistical analysis
Data were analyzed using the Mann-Whitney test. Cor-
relations were calculated using Pearson correlation and
graphed showing the linear regression. All analyses were
performed using Prism software (GraphPad Software, Inc.).
Differences were considered significant at a P-value <0.05.
Results
Study patients
All patients selected met the criteria for dcSSc according
to diagnostic [21] and subtype criteria [22]. The MRSS
[22] was used to determine the extent of skin involve-
ment [23]. The mean age for these patients (n = 24) was
48 ± 11 years (mean ± standard error of the mean
(SEM)) with 68% (n = 17) of those studied being female.
The average MRSS was 23 ± 11. Of the patients studied,
45% (10 out of 22 patients) were receiving treatment at
the time of the biopsy. The mean age for the healthy
controls was 40 ± 16 years, and 45% were female.
Stifano et al. Arthritis Research & Therapy 2014, 16:R136 Page 4 of 13
http://arthritis-research.com/content/16/4/R136TLR4-complex expression in skin from patients with dcSSc
In order to explore TLR4 and its co-receptors in the skin
of dcSSc patients, we analyzed the mRNA level of TLR4,
CD14, and MD2. Lesional skin from dcSSc patients
showed significantly higher levels of TLR4 mRNA com-
pared to skin samples from healthy controls. (Figure 1A;
TLR4, 2-fold increase, P <0.01). DcSSc skin samples also
showed significantly higher expression of the co-receptors
CD14 and MD2 (Figure 1B,C CD14, 2.4-fold increase,
P <0.0001; MD2, 1.8-fold increase, P <0.05) compared to
skin from healthy controls.
To better understand whether TLR4 and co-receptor
expression might contribute to pathogenesis, we exa-
mined the relationship between the expression of TLR4
and its co-receptors to the MRSS, a measure of the de-
gree of skin fibrosis in SSc patients [26]. Unlike several
biomarkers we have reported previously [27], the MRSS
did not correlate with expression of TLR4, CD14 or
MD2 (data not shown). Although the MRSS assesses
skin disease at the time it is scored, this single measure
does not provide information about the disease tra-
jectory, that is, whether skin fibrosis is progressively in-
volving more skin and/or more severely involving skin
already affected by the disease process. Comparing the
MRSS at the time of the biopsy to a later point in time
can make an assessment of disease activity. This is par-
ticularly important because we know that skin disease in
dcSSc patients cannot only stabilize, but also regress in a
significant fraction of patients [28]. Thus we assessedFigure 1 Overexpression of Toll-like receptor 4 (TLR4)-complex genes in
(A-C) Gene expression comparing dcSSc patients (SSc, n = 24, solid squares) t
change, normalized to mRNA expression by q-PCR, all expression normalized
(C) show average SSc mRNA expression increased, respectively, by 2-fold (P <
standard error of the mean. In the dot plot, each data point represents a sing
skin score; change in skin score was calculated as the difference in the modifi
(D) TLR4 gene expression (r2 = 0.3, P = 0.02); (E) CD14 gene expression (r2 = 0.the relationship between TLR4 and co-receptors with pro-
gressive skin disease, using delta-MRSS (ΔMRSS), that is,
the change in the MRSS at 6 months after the skin biopsy
compared to the baseline MRSS assessed at the time of
the skin biopsy. For the patients included in our study, the
range of ΔMRSS (calculated for 18 patients) was from −20
to 10. TLR4 and MD-2 expression correlated modestly
but significantly with ΔMRSS (TLR4: r2 = 0.3, P = 0.02;
MD-2: r2 = 0.23, P = 0.04) (Figure 1D, F). Strikingly,
CD14 mRNA expression correlated highly with ΔMRSS
(r2 = 0.62, P = 0.0002) (Figure 1E), indicating an important
connection between CD14 expression and progressive
disease in dcSSc patients.
Chronic dermal LPS exposure induces inflammation in
mouse skin
To better understand the effect in skin of TLR4
activation in vivo, we tested the effect of continuous
stimulation with LPS for 1 or 4 weeks by subcutaneous
osmotic pump. Skin histology from the infused site of
mice treated with LPS for 1 or 4 weeks showed similar
striking inflammation in the subcutaneous, deep dermis,
and fat layers (Figure 2A-D).
To further investigate the effect of LPS in skin, we ana-
lyzed expression of proinflammatory genes: IL-1β, IL-6,
and TNF-α. All three of these inflammatory cytokines
were strikingly elevated in mice treated with LPS for
1 week compared with controls, PBS treated mice (IL-1β,
43.79-fold P <0.0001; IL-6, 15.74-fold; P <0.0001; andskin from diffuse cutaneous systemic sclerosis (dcSSc) patients.
o healthy controls (HC, n = 11, solid circles). Data are expressed as fold-
to one HC: TLR4 (A), CD14 (B) and Myeloid differentiation factor 2 (MD2)
0.01); 2.4-fold (P <0.0001), and 1.8-fold (P <0.05). Bars show the mean ±
le skin sample. (D-F) Correlation between gene expression and change in
ed Rodnan skin score over 6 months (ΔMRSS). Correlation of ΔMRSS with:
62, P = 0.0002); and (F) MD2 gene expression (r2 = 0.23, P = 0.04).
Figure 2 Toll-like receptor 4 (TLR4) activation induces inflammation and cellular infiltration. (A-D) Representative figure of H&E-stained
cross-section of skin from C57Bl6/wild-type (WT) mouse after treatment with PBS or lipopolysaccharide (LPS) with subcutaneous pumps for 1 week
(WT-PBS-1w or WT-LPS-1w: A, B) or 4 weeks (WT-PBS-4w or WT-LPS-4w: C, D). (E-L) Relative expression of mRNA by nanostring in 1-week, LPS-treated
(n = 13, solid circles) compared to PBS-treated (n = 6, open circles) WT mice, and 4-week, LPS-treated (n = 5, solid triangles) compared to PBS-treated
(n = 7, open triangles) WT mice, **P <0.01, ****P <0.0001. In the dot plot, each data point represents a single sample. Increased gene expression of
proinflammatory markers in LPS- compared to PBS-treated mice at 1 week and 4 weeks: (E) IL-1β: 1 week, P <0.0001; 4 weeks, P <0.01. (F) IL-6: 1 week,
P <0.001; 4 weeks, P <0.01. (G) TNF-α: 1 week, P <0.0001; 4 weeks, P <0.01. (H) CD14: 1 week, P <0.0001; 4 weeks, P <0.01. (I) F4/80: 1 week, P <0.0001;
4 weeks, P <0.01. (J) CD11b: 1 week, P <0.0001; 4 weeks, P <0.001. (K) Flow cytometry: representative plots of CD11b+ high-scatter (CD11b+SSChi) and
low-scatter (CD11b+SSClo) cells, isolated from skin of WT mice treated with PBS or LPS for 1 week. (L-N) Percentage of cells, CD11b+ (L), CD11b+SSChi
(M), and CD11b+SSClo (N) cells in LPS-treated WT mice (n = 3) compared with PBS-treated WT mice (n = 3), for 1 week. Each bar represents the
mean ± standard error of the mean.
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from mice treated for 4 weeks with LPS showed a less
striking increase in IL-1β, IL-6, and TNF-α (IL-1β, 25.24-
fold, P <0.01; IL-6, 6.81-fold, P <0.01; TNF-α, 3.50-fold
increase, P <0.01; Figure 2E-G).
Chronic dermal LPS exposure recruits macrophages and
granulocytes
In order to quantitatively define the inflammatory cell
types recruited to the skin by LPS treatment, we analyzed
the expression of immune cell markers using flow cytome-
try on cells extracted from treated skin (Figure 2K-N).
After 1 week of LPS treatment we found a remarkable
increase of CD11b-positive cells (56%, mean of three ex-
periments of CD11b+ cells) compared to PBS-treated skin
(13%, mean of three experiments of CD11b+ cells) (WTPBS compared to WT LPS: 4.1-fold increase in the per-
centage of cells; Figure 2L). This population could be fur-
ther divided based on the expression of CD11b and side
scatter (SSC), a measure of cell granularity or internal
complexity. We found two groups of cells: CD11b+SSClo
(identifying macrophages), and CD11b+SSChi (identifying
granulocytes). Both of these populations were increased in
LPS-treated skin compared to PBS-treated control skin
(CD11b+SSChi, 3.6-fold increase in percentage of cells;
CD11b+SSClo, 6.1-fold increase in percentage of cells,
Figure 2M-N). The highly induced infiltration of these
two cell types is consistent with histologic evaluations
noted above (see Figure 2A-D). In contrast, the number of
T cells and B cells (marked with CD3 and B220, respec-
tively) did not show any difference between mice treated
with LPS compared to PBS-treated skin (data not shown).
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macrophage markers, including CD14 (9.54-fold increase,
P <0.0001), F4/80 (3.32-fold increase, P <0.0001), and
CD11b (5.27-fold increase, P <0.0001) after 1 week of LPS
(Figure 2H-J). We also observed significant changes in
mRNA levels of these genes at 4 weeks (CD14, 6.78-fold
increase, P <0.01; F4/80, 4.52-fold increase, P <0.01;
CD11b, 4.12-fold increase, P <0.01; Figure 2H-J). In
contrast to these monocyte/macrophage markers and con-
sistent with our flow cytometry analyses, mRNA levels of
T-cell (CD3) and B-cell (CD19) markers showed no
change in LPS-treated compared to PBS-treated control
skin at 1 or 4 weeks (data not shown).Figure 3 Lipopolysaccharide (LPS) induces overexpression of M1 and M
signature genes. (A-F) Gene expression by nanostring, comparing 1-week,
wild-type (WT) mice; and 4-week LPS- (n = 5, solid triangles) with PBS-treate
plot, each data point represents a single sample. Increased gene expression
(A) NOS2, 1 week, P <0.0001; 4 weeks, P < 0.001. (B) Arginase-1 (ARG-1), 1 w
P <0.01. (D) Plasminogen activator inhibitor-1 (PAI-1), 1 week, P <0.0001; 4
TIMP1, 1 week, P <0.0001; 4 weeks, P <0.01. (G-L) Representative images of
from WT mice treated with PBS (WT-PBS: G, I, K) or LPS (WT-LPS: H, J, L) foDermal LPS exposure activates M1 and M2 macrophages
To characterize the M1 and M2 phenotype of macrophages
recruited by LPS, we analyzed expression of mRNA levels
of the M1 macrophage marker NOS2 (Figure 3A), and M2
macrophage markers, ARG-1 and YM1 (Figure 3B, C).
Although TLR4 activation in vitro is typically associated
with M1 macrophages, both the M1 marker, NOS2, and
the M2 markers, ARG-1 and YM1, were strikingly and
significantly increased in mice treated with LPS for 1 week
(NOS2, 18.03-fold increase, P <0.0001; ARG-1, 10.98-fold
increase, P <0.0001; YM1, 18.20-fold increase, P <00001).
After 4 weeks of LPS treatment, we observed a less stri-
king increase of the M1 and M2 macrophage markers2 macrophage markers, and transforming growth factor (TGF)-β
LPS- (n = 13, solid circles) with PBS- (n = 6, open circles) treated
d (n = 7, open triangles) WT mice. **P <0.01, ****P <0.0001. In the dot
in LPS- compared to PBS-treated WT mice of macrophage markers:
eek, P <0.0001; 4 weeks, P <0.01. (C) YM1, 1 week, P <0.0001; 4 weeks,
weeks, P <0.01. (E) SPP1, 1 week, P < 0.0001; 4 weeks, P <0.01. (F)
MAC-3 (G, H), CD163 (I, J), and ARG-1 (K, L) staining on skin section
r 1 week.
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increase, P <0.01; YM1, 5.08-fold increase, P <0.01;
Figure 3A-C).
Immunostaining on paraffin sections of Mac-3, a gen-
eral marker for macrophages (Figure 3G, H), and CD163
(Figure 3I, J) and ARG-1 (Figure 3K, L), M2 markers sup-
ported above observations. Highly increased numbers of
CD163- and ARG-1-positive cells stained primarily in the
subcutaneous region of mice treated with LPS for 1 week
compared with PBS-treated controls. Mac-3-positive cells
were well-distributed in all skin layers, mostly in the LPS-
treated mice compared to the PBS controls. After 4 weeks,
we observed more Mac3-, CD163- and Arg-1-positive
cells in the skin of mice treated with LPS compared with
controls, but the staining was much less intense compared
to staining in 1-week LPS-treated mice, consistent with
the lower level of M2 gene expression (Additional file 1).
LPS treatment induces pro-fibrotic gene expression and
fibrosis
Recent studies have suggested that TLR4 activation is in-
volved in the amplification of fibrosis and TGF-β re-
sponses in SSc, and TLR4 activation has been implicated
in other fibrotic diseases [17-19]. To investigate the poten-
tial role of TLR4 activation in vivo, we monitored the ex-
pression of several TGF-β regulated genes in our murine
model. We have recently identified several genes regulated
by TGF-β in mouse skin [3], that are also increased in the
skin of dcSSc patients, including PAI-1 (Serpine-1) [27],
SPP1 (osteopontin 1), and TIMP1 (tissue inhibitor metal-
loproteinase 1, unpublished data). After 1 week of LPS
treatment, we observed significantly increased expression
of PAI-1 (15.01-fold increase, P <0.0001; Figure 3D), SPP1
(9.14-fold increase, P <0.0001; Figure 3E), and TIMP1
(10.77-fold increase, P <0.0001; Figure 3F), in LPS-treated
mice (Figure 3D-F). Additionally, we found increased
expression of other TGF-β regulated genes: COL5A1
(Collagen type 5, alpha 1), LOX (lysyl oxidase), SFRP2
(Secreted frizzled-related protein 2), MMP13 (matrix
metallopeptidase 13), MMP3 (matrix metallopeptidase 3),
WISP1 (WNT1-inducible-signaling pathway protein 1),
and THBS1 (thrombospondin 1) in the mice treated with
LPS after 1 and 4 weeks compared to the controls
(Additional file 2). We observed similar increases in TGF-
β-regulated genes in LPS-treated skin at 4 weeks (PAI-1,
11.22-fold increase, P <0.01; SPP1, 9.14-fold increase,
P <0.01; TIMP1, 9.24-fold increase, P <0.01; Figure 3D-F).
Inhibition of TGF-β signature gene expression in LPS-treated
mice by anti-TGF-β antibody (α-TGF-β) treatment and upon
macrophage depletion
As upregulated TGF-β signature genes were observed in
LPS-treated mouse skin, we tested whether α-TGF-β
would block expression of these genes. Mice treated withα-TGF-β showed a remarkable reduction in the expression
of PAI-1 (LPS-treated, WT-IgG compared to WTα-
TGF-β, 2.53-fold decrease, P = 0.06), TIMP1 (LPS-treated,
WT-IgG compared to WT α-TGF-β, 1.88-fold decrease,
P <0.05), THBS1 (LPS-treated, WT-IgG compared to
WTα-TGF-β, 2.01-fold decrease, P <0.05) and COLA1A
(LPS-treated, WT-IgG compared to WTα-TGF-β, 1.5-fold
decrease, P <0.05) compared to control mice treated with
isotype-matched Ig (Figure 4A-D). Supervised clustering
of the cutaneous gene expression of these mice, showed
other genes that were significantly reduced after α-TGF-β
treatment, such as CXCL5, CD14, CD11b and IL-6, sug-
gesting that the expression of these genes is induced by
TGF-β in our model (Figure 4E, F).
To further investigate the pro-fibrotic mechanism
induced by LPS and related to the activation of M2
macrophages, we tested chronic LPS exposure in a
macrophage-deficient model. Transgenic mice selectively
expressing the diphtheria toxin receptor (DTr) in CD11b+
cells were treated with DT or PBS (control) and LPS
pumps inserted subcutaneously. Mice injected with DT
(Figure 4G, CD11b-DTr LPS/DT) did not show the stri-
king cellular infiltration (Figure 4H, CD11b-DTr LPS/DT)
or the overexpression of inflammatory genes (data not
shown) seen in control mice. Despite only partial deple-
tion of macrophages in the skin treated with LPS, as
shown by the presence of some CD163- and ARG-1-
positive cells (Figure 4I-L), the expression of most of the
pro-fibrotic genes were significantly decreased compared
to the controls, PAI-1 (LPS-treated mice, CD11b-DTr
LPS/PBS compared to CD11b-DTr LPS/DT, 2.53-fold
decrease, not significant, P = 0.06; Figure 4K) and PBS
compared to CD11b-DTr LPS/DT, 3.32-fold decrease,
P = 0.06; Figure 4L). Other inflammatory and pro-fibrotic
genes were also significantly blocked such as, IL-1 β, IL-6,
COLA1A, WISP and MMP12 (data not shown).
Inhibited proinflammatory and pro-fibrotic effects of LPS
in TLR4- and MyD88- deficient mice
To define the contribution of TLR4 activation and the
consequent recruitment and activation of the adaptor
molecule MyD88, to inflammation and fibrosis, we tested
LPS treatment in TLR4- and MyD88-deficient mice for
1 week by subcutaneous osmotic pump. H&E staining
from LPS-treated, TLR4- and MyD88-deficient mice
showed an important reduction of cellular infiltration in
the subcutaneous layer (Figure 5B, C), compared to the
WT LPS-treated mice (Figure 5A). Furthermore, we ob-
served that the expression of inflammatory cytokines,
TNF-α and IL-6, were almost completely blocked in
skin of LPS-treated, TLR4- and MyD88- deficient mice
compared to WT mice (TNF-α, LPS-treated WT com-
pared to TLR4−/−, 7-fold decrease, P <0.001; LPS-treated,
WT compared to MyD88−/−, 50.49-fold decrease, P <0.05;
Figure 4 Transforming growth factor (TGF)-β signature gene is reduced after anti-TGF-β antibody (α-TGF-β) injection and after
macrophage depletion. (A-D) Gene expression by nanostring, comparing 1-week, distal skin (DS, open squares) with local skin (LS, solid squares)
from lipolysaccharide (LPS)-wild-type (WT) mice, treated with IgG by intraperitoneal (i.p.) injection (n = 4), and 1-week, DS (open diamonds) with LS
(solid diamonds) from LPS-WT mice, treated with α-TGF-β by i.p. injection (n = 4). Pro-fibrotic genes: (A) plasminogen activator inhibitor-1 (PAI-1);
(B) tissue inhibitor metalloproteinase 1 (TIMP1); (C) thrombospondin 1 (THSB1), and (D) collagen type 1, alpha 1 (COL1A1). (E,F) Heat map of genes
clustered using complete linkage, hierarchical, supervised clustering, and summury table in DS and LS from LPS-pump WT mice treated with IgG i.p
(DS WT-LPS IgG and LS WT-LPS IgG), or α-TGF-β i.p. (DS WT-LPS α-TGF-β and LS WT-LPS α-TGF-β). (F) Averages of gene expression of DS from
IgG- (Ctlr-IgG), α-TGF-β-treated mice (Ctrl α-TGF-β), and of LS from IgG- (LS-IgG), α-TGF-β-treated mice (LS α-TGF-β). Last column: percentage of reduction
in the expression of each gene (% of rdc) and the significance (p) between LS α-TGF-β and LS-IgG. (G-J) Representative of H&E (G, H), CD163 (I, J), and
ARG-1 (K, L) staining cross-section of skin from CD11b-DTr mouse after LPS pump treated with PBS (DTr-LPS PBS i.p: G, I, K) or DT (DTr-LPS DT i.p: H, J, L).
Decreased gene expression of LPS-induced TFG-β signature in genes in CD11b-DTr after DT (CD11b-DTr-DT): (M) PAI-1 and (N) TIMP1.
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decrease, not significant, P = 0.6; LPS-treated, WT com-
pared to MyD88−/−, 304.37-fold decrease, P <0.001; Fig-
ure 5K, L). In contrast, IL1β was blocked in LPS-treatedMyD88-deficient mice, but showed only a trend toward
partial inhibition in LPS-treated TLR4-deficient mice
compared to controls (IL1β, LPS-treated, WT compared
to TLR4−/−, 5.7-fold decrease, P <0.01; LPS-treated, WT
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Figure 5J).
To further investigate signals mediating macrophage
activation, we analyzed M1 and M2 macrophage
markers in TLR4- and MyD88-deficient mice. LPS-
treated, TLR4- and MyD88-deficient mice showed few
CD163- and ARG-1-positive cells compared to LPS-
treated WT mice (Figure 5D-I). mRNA levels of CD11b
(Figure 5M), and the M2 marker, YM1 (Figure 5N), were
significantly reduced in LPS-treated, TLR4- and
MyD88-deficient mice compared to LPS-treated WT
mice (LPS-treated, WT compared to TLR4−/−, CD11b,
1.70-fold decrease, P <0.001; YM1, 3.48-fold decrease,
P <0.05; LPS-treated, WT compared to MyD88−/−,
CD11b, 1516.06-fold decrease, P <0.001; YM1, 172.64-
fold decrease, P <0.001; Figure 5M, N). NOS2 ex-
pression was completely blocked in LPS-treated
MyD88-deficient mice, but not in LPS-treated TLR4-
deficient mice (LPS-treated, WT compared to TLR4−/−,
1.90-fold decrease, not significant, P = 0.22; LPS-treated,
WT compared to MyD88−/−, 218.34-fold decrease,
P <0.001; Figure 5O).
Notably, induction of TGF-β genes was completely
blocked in LPS-treated, MyD88- deficient mice
(THBS1, WT compared to MyD88−/−, 2,409.04-fold
decrease, P <0.001; TIMP1, LPS-treated, WT compared to
MyD88−/−, 3,249.62-fold decrease, P <0.001; PAI −1,
LPS-treated, WT compared to MyD88−/−, 3,466.56-fold
decrease, P <0.001; SPP-1, LPS-treated, WT compared to
MyD88−/−, 2,908.35-fold decrease, P <0.001; Figure 5P-S).
THSB1 and TIMP1 were also significantly decreased in
LPS-treated TLR4-deficient mice but slightly increased
compared to the controls (THBS1, LPS-treated, WT com-
pared to TLR4−/−, 1.95-fold decrease, P <0.001; TIMP1,
LPS-treated, WT compared to TLR4−/−, 1.66-fold de-
crease, P <0.01; Figure 5P, Q). On the other hand, in LPS-
treated, WT and TLR4-deficient mice, mRNA levels of
PAI-1 and SPP-1 were similar (PAI-1, LPS-treated, WT
compared to TLR4−/−, 1.18-fold decrease, not significant,
P = 0.36; SPP-1, LPS-treated, WT compared to TLR4−/−,
0.63-fold increase, not significant, P = 0.20; Figure 5R, S).
As TLR4-deficient mice still responded partially to LPS, we
also tested LPS in TLR2-deficient mice. However, TLR2-
deficient mice showed no difference in gene expression
compared to WT, LPS-treated mice (Additional file 3).
Discussion
We show here that TLR4 co-receptors, CD14 and MD2,
are overexpressed in the skin of dcSSc patients. As CD14
is expressed mainly on macrophages and monocytes, these
current findings are in line with previous studies pub-
lished by our group, showing that the macrophage mar-
kers, Siglec1 (sialic acid-binding immunoglobulin-type
lectin-1) and MRC1 (mannose receptor-1) are increasedin lesional skin in SSc [3,29], suggesting an important
function of innate immunity and particularly of macro-
phages in the tissue inflammation and fibrosis of skin in
SSc. Expression of MD2, TLR4 and, most strikingly, CD14
correlated with progressive skin disease, as assessed by the
change in MRSS 6 months after the skin biopsy was per-
formed. Thus, expression of these genes and in particular
CD14 appears to be the first prognostic biomarker identi-
fied in SSc skin. Prognostic biomarkers are particularly
important in this disease because of the extremely variable
course of skin disease, progressing in some patients while
regressing in others, and because clinical markers of dis-
ease provide limited information about disease trajectory
[30]. CD14 expression may provide important information
about the likelihood of progression and thus the need for
treatment. As most of the patients in this study were
taking some type of immunosuppressive medication, these
correlations may be confounded by the treatment re-
gimen, the most likely effect to decrease the apparent
degree of correlation, because patients responding to a
treatment might deviate from the anticipated natural his-
tory. Therefore, these correlations may underestimate the
prognostic utility of CD14 expression, however, further
studies will be required to clarify how strongly CD14
expression in the skin correlates with progressive skin
disease.
Chronic skin exposure to endotoxin (LPS) induced in-
flammation, cellular recruitment and activation of TGF-β
signature genes. It is well known that LPS is a powerful
immunostimulant, and indeed, LPS-treated mice, at both
1 and 4 weeks, showed inflammation, characterized by
macrophage infiltration and induction of proinflammatory
chemokines. However, chronic stimulation of TLR4 at a
low concentration of LPS can induce endotoxin tolerance
characterized by a transient unresponsive state, reduced
proinflammatory response, cellular desensitization, and
cellular reprogramming [31]. This has been attributed to
induction by LPS of a variety of immune modulators,
including IRAK-M, SOCS-1, and IL-10 [32]. In our study,
we found that the levels of the proinflammatory che-
mokines in 4-week LPS-treated mice were lower than in
1-week LPS-treated mice, suggesting that longer activation
of TLR4 might induce endotoxin tolerance, activating
counter-regulatory processes that limit inflammation.
Pathways activated by endotoxin tolerance might
explain the presence of M2 macrophages found most
strongly at 1 week in LPS-treated mice: 1-week LPS-
treated mice showed severe macrophage and granulocyte
infiltration, the first cells recruited in the early phase of
inflammation. These findings are consistent with the
markedly increased staining of Mac-3, a general marker
for macrophages, and Arg-1 and CD163, M2 macro-
phage markers, in 1-week LPS treated skin. These data
suggest that LPS stimulation activates both M1 and M2
Figure 5 Effects of lipopolysaccharide (LPS) treatment are partially inhibited in Toll-like receptor 4 (TLR4)-deficient mice and blocked
in Myeloid differentiation factor 88 (MyD88)-deficient mice. (A-F) Representative of H&E (A-C), CD163 (D-F), and arginase-1 (ARG-1) (G-I) staining
cross section of murine skin after LPS-pump in wild-type (WT) (A, D, G), TLR4−/− (B, E, H) or MyD88−/− (C, F, I)mice. (J-R) Gene expression in skin of
WT, TLR4−/− and MyD88−/− mice treated for 1 week with PBS: WT (n = 6, open circles) TLR4−/− (n = 2, open triangles), MyD88−/− (n = 4, open
diamonds); or with LPS: WT (n = 13, solid circles) TLR4−/− (n = 5, solid triangles), MyD88−/− (n = 6, solid diamonds); *P <0.05, ** P <0.01, *** P <0.001,
ns = not significant. Proinflammatory genes: (J) IL-1β, (K) TNF-α, and (L) IL-6. Macrophage markers: (M) CD11b; M2 and M1 macrophages: (N) YM1
and (O) NOS2. Pro-fibrotic genes: (P) thrombospondin 1 (THBS1), (Q) tissue inhibitor metalloproteinase 1 (TIMP1), (R) plasminogen activator
inhibitor-1 (PAI-1) and (S) osteopontin 1 (SPP1).
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human macrophages, showing that endotoxin tolerance
induces M2 as well as M1 macrophages. M2 macro-
phages may be important in the pro-fibrotic response
either by directly releasing pro-fibrotic cytokines or by
recruiting other cell types that regulate extracellular
matrix turnover [33,34].
TGF-β signature genes, PAI-1 and TIMP1, showed
highly increased expression at both 1- and 4-week time
points, showing that chronic exposure to endotoxin
actives pro-fibrotic gene expression. We have recently
shown that PAI-1 and SPP1 are overexpressed in the
skin of mice treated with TGF-β [3]. Collagen deposition
was located mostly in the fascia, rather than the dermis,indicating that LPS and the associated inflammatory
response is localized to the site of ligand release. Other
in vivo studies support several in vitro studies, showing
that TLR4 activation regulates the TGF-β pathway [20].
Furthermore after LPS exposure the reduction of TGF-β
regulated genes, following the injection of anti-TGF-β or
macrophage depletion, indicates the involvement of
TLRs and mostly MyD88 pathway activation in the in-
duction of a TGF-β signature in the skin. The reduction
of pro-fibrotic gene expression after macrophage deple-
tion shows the significant involvement of the macro-
phages in the production or activation of TGF-β.
To examine the receptor utilized by LPS in our model,
we compared the effect of LPS treatment in TLR4- and
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still responded partially to LPS, showing nearly the same
increases in IL-1β, but largely blocked IL-6, TNF-α
responses, and cellular infiltration of M2 macrophage
markers. LPS also induced some TGF-β responsive genes
(PAI-1 and SPP1) in TLR4-deficient mice, whereas dele-
tion of MyD88 blocked all TGF-β regulated gene expres-
sion. Although LPS responses seem to generally depend
on TLR4 expression [35], LPS has been described to ac-
tivate other receptors, mainly expressed on macrophages
(β-2 integrins, CD11/CD18, moesin, decay accelerating
factor (DAF) and CD55) [36-38] or can be sponta-
neously internalized [38,39]. Our data might suggest that
in TLR4-deficient mice LPS actives one of these or other
alternative receptors on resident skin cells, macrophages,
fibroblasts, keratinocytes, dendritic or endothelial cells.
In our model, TLR4 seems to be necessary for macro-
phage activation. These non-TLR4-mediated effects do
not appear to depend on TLR2, as expression in TLR2-
deleted mice was similar to WT mice. The complete
inhibition in MyD88-deleted mice strongly supports the
importance of this pathway in TLR4-mediated fibrosis.
Taken together, our findings suggest that the pro-fibrotic
and inflammatory signature of our chronic LPS skin
model is dependent on MyD88 and might suggest its
importance in SSc pathogenesis.
Conclusion
In conclusion, we showed that TLR4 co-receptors, CD14
and MD2, are overexpressed in the skin of dcSSc patients.
Expression of these genes, and in particular CD14, appears
to be the first prognostic biomarker identified in SSc skin.
In the murine skin, chronic exposure to LPS induced in-
flammation, cellular recruitment and activation of TGF-β
signature genes. We delineated the role of MyD88 as
necessary for the induction not only for the early phase of
inflammation, but also for pro-fibrotic gene expression via
activation of macrophages. Chronic LPS exposure might
be a model for the early stage of SSc when inflammation
and macrophage activation are important pathological
features of the disease. This supports a role for innate
immune activation in SSc skin fibrosis, suggesting its
importance in SSc pathogenesis.
Additional files
Additional file 1: M1 and M2 markers in 4-week treated mice.
Representative images of Mac-3, (A, B), CD163 (C, D), and arginase-1
(ARG-1) (E, F) staining on skin section from wild-type (WT) mice treated
with PBS (WT-PBS: G, I, K) or LPS (WT-LPS:H, J, L) for 4 weeks.
Additional file 2: Pro-fibrotic gene expression in lipopolysaccharide
(LPS)-treated skin. Pro-fibrotic gene expression in 1- and 4-week LPS-treated
mice. In the second and third columns, it is reported as the fold-increase for
each pro-fibrotic gene described in the first column, respectively in mice and
in 4-week LPS-treated mice (Fold inc. 1-week and Fold inc. 4-week). In thelast 2 columns, the P-values for each pro-fibrotic gene are reported (P-value
1-week and P-value 4-week). Fold-increase is calculated as the ratio of the
mean of wild-type (WT) LPS-treated and WT PBS-treated mice gene
expression.
Additional file 3: Toll-like receptor 2 (TLR2) deficiency does not
block lipopolysaccharide (LPS)-induced gene expression. Gene
expression by nanostring, comparing 1-week LPS-treated mice, Distal skin
(DS) with local skin (LS) from wild-type (WT) (open circles, DS (n = 2); closed
circles, LS (n = 13)), TLR4-/- (open triangles, DS (n = 2); closed triangles, LS
(n = 5)) and TLR2-/- (open diamonds, DS (n = 2); closed diamonds, LS
(n = 3)) mice, *P <0.05; **P <0.01; ***P <0.001; ****P <0.0001; ns, not significant.
In the dot plot, each data point represents a single sample, and the axis a
log scale. (A) IL-1β (LPS-treated, TLR4-/- compared to WT: 5.07-fold decrease,
P <0.01; LPS-treated, TLR2-/- compared to WT: 1.25-fold decrease, ns P= 0.71);
(B) THBS1 (LPS-treated, TLR4-/- compared to WT: 1.95-fold decrease, ***P
<0.001; LPS-treated, TLR2-/- compared to WT: 1.32-fold decrease, ns, P= 0.20);
(C) PAI-1 (LPS-treated, TLR4-/- compared to WT: 1.18-fold decrease, ns,
P= 0.36; LPS-treated, TLR2-/- compared to WT: 0.75-fold decrease, ns, P = 0.24)
and macrophages markers (D) CD11b (LPS-treated, TLR4-/- compared to WT:
1.70-fold decrease, ***P <0.001; LPS-treated, TLR2-/- compared to WT: 0.9-fold
decrease, ns, P = 0.61); (E) NOS2 (LPS-treated, TLR4-/- compared to WT: 1.90-
fold decrease, ns, P= 0.29; LPS-treated, TLR2-/- compared to WT: 1.23-fold
decrease, ns, P = 0.90; and (F) YM-1 (LPS-treated, TLR4-/- compared to WT:
3.44-fold decrease, ns, P = 0.09; LPS-treated, TLR2-/- compared to WT: 1.17-fold
decrease, ns, P = 0.63).
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ARG-1: arginase-1; BB20 NOS2: nitric oxide synthase; CD11b: cluster of
differentiation molecule 11b; CD14: cluster of differentiation molecule 14;
CD163: cluster of differentiation molecule 163; CD18: cluster of differentiation
molecule 18; CD3: cluster of differentiation molecule 3; CD55: cluster of
differentiation molecule 55; cDNA: complementary DNA; COL1A1: collagen
type 1, alpha 1; COL5A1: collagen type 5, alpha 1; CTGF: connective tissue
growth factor; CXCL5: C-X-C motif chemokine 5; DAF: decay accelerating
factor; DAMPs: damage associated molecular patterns; dcSSc: diffuse
cutaneous SSc; DT: diphtheria toxin; DTR: diphtheria toxin receptor;
ECM: extracellular matrix; Fn-EDA: fibronectin extradomein A;
H&E: hematoxylin and eosin; HMGB1: high mobility group box 1 protein;
Hsp: heat-shock proteins; IL: interleukin; Itgam: integrin alpha M;
LBP: lipopolysaccharide-binding protein; LOX: lysyl oxidase;
LPS: lipopolysaccharide; MD2: myeloid differentiation factor-2; MMP: matrix
metallopeptidase; MRSS: modified Rodnan skin score; MyD88: myeloid
differentiation factor 88; OCT: optimal cutting temperature compound;
PAI-1: plasminogen activator inhibitor-1; PAMPs: pathogen associated
molecular patterns; PBS: phosphate buffered saline; qPCR: quantitative
real-time polymerase chain reaction; RPMI: Roswell Park Memorial Institute
medium; SFRP2: Secreted frizzled-related protein 2; SLE: systemic lupus
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TGF-β: transforming growth factor-β; THBS1: thrombospondin 1; TICAM: Toll-
interleukin 1 molecule-containing adaptor molecule; TIMP1: tissue inhibitor
metalloproteinase 1; TIR: Toll-interleukin 1 (IL-1) receptor; TLR: Toll-like
receptor; TNF-α: tumor necrosis factor-α; TSLP: thymic stromal lymphopoietin;
WISP1: WNT1-inducible-signaling pathway protein 1; WT: wild-type;
α-TGF-β: anti-transforming growth factoer-β antibodies; ΔMRSS: delta
modified Rodnan skin score.
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